Onkai uses liquid biopsy diagnostic technology, which only requires a tube of blood to be collected. By detecting and analyzing the degree of DNA methylation, it can determine whether the patient has a tumor and determine the type and progression of the tumor.

1. Physical examination population
2. Auxiliary diagnosis
3. Risk population management
4. Recurrence monitoring

1. Early diagnosis: It can detect very low concentrations of cancer signals in the bleeding fluid, with high specificity and sensitivity, and can be detected before small lesions develop into visible tumors, with a high early detection rate;
2. Four cancer joint examination: gastrointestinal, liver, and pancreas, one test, no need to travel back and forth between different departments;
3. Easy to operate: only one tube of blood is needed, non-invasive and non-invasive;
4. Repeated sampling: monitoring treatment response, minimal residual lesions, recurrence and metastasis at any time;
5. Wide applicability: It can detect the progression of symptomatic patients and evaluate the cancer risk of asymptomatic populations;
6. Light economic burden: Early screening can lead to early diagnosis, and early diagnosis can reduce costs, avoiding the huge treatment costs and regret of life caused by delayed screening and diagnosis.
7. High social benefits: Early screening for cancer can reduce the overall social burden.

Hypersensitivity joint inspection: 10 ml blood is collected at one time, and liver cancer, gastric cancer, colorectal cancer, pancreatic cancer are detected early
Accurate warning: high sensitivity 88%, high specificity 92%, accurate warning of disease risk, precancerous lesions, early cancer
Accurate positioning: High organizational traceability accuracy of 81%; Accurately locate the source organ of the tumor and guide the next clinical examination accurately
Safe and convenient: Blood testing is safe and fast; Non invasive and non radioactive hazards